CD274 and neoplasm: Additionally, tumor tissues were collected at sacrifice to measure tumor weights, revealing a 67% reduction in tumor weight with TAVO423 treatment, compared to a 37% reduction with PD-L1 × HYAL treatment (Figure 4C).